22 SHARE-BASED PAYMENTS (CONTINUED) Movement in the number of share options on issue: 2026 2025 Number of Options Weighted Average Exercise Price ($) Number of Options Weighted Average Exercise Price ($) Total Options Outstanding at the beginning of the year 18,528,913 $0.981 8,955,756 $1.149 Granted (ESOP) 700,000 $0.525 1,150,000 $0.949 Granted (Other) – – 9,753,913 $1.000 Forfeited (2,175,000) $0.889 – – Exercised – – – – Expired (1,225,000) $0.993 (1,330,756) $2.488 Outstanding at year-end 15,828,913 $0.945 18,528,913 $0.962 Exercisable at year-end 14,262,250 $0.972 13,687,247 $0.981 OPTIONS RESERVE The number of options granted during the year pursuant to the ESOP was 700,000 (2025: 1,150,000), while no employee share options were exercised (2025: nil) and 3,400,000 employee options expired/forfeited during the financial year (2025: 1,330,756). The value of employee share options issued during the financial year has been calculated by using a modified binomial option pricing model applying the following inputs: Exercise prices $0.506 and $0.596 Underlying share prices Between $0.335 and $0.40 Days to expiration 1,461 to 1,826 Days to vesting 365 to 1,096 Expected share price volatility 85% Risk free interest rate Between 4.26% and 4.29% Historical volatility is assumed to be indicative of future volatility however future volatility may not replicate historical volatility. The life of the options is based on the contracted expiry date. In the prior year, 9,378,913 listed options were issued in conjunction with the 2024 capital raise and also a further 375,000 listed options were issued in exchange for investor relations services. RECOGNISED SHARE-BASED PAYMENT TRANSACTIONS Share based payment transactions recognised as operating expenses in the statement of comprehensive income during the financial years were as follows: For the year ended 30 June 2026 $ For the year ended 30 June 2025 $ Share expense for ESS plan issued during the year 33,024 11,008 Options expense/(credit) for options issued during the year(i) (120,096) 813,555 (87,072) 824,563 (i) Options grant expense for options issued during the year Notes to the Financial Statements continued for the year ended 30 June 2026 56 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3